stockrow
Friday 6 November 2026
Export DNTH’s income statement to Excel — free account
Dianthus Therapeutics, Inc.
DNTH Healthcare Biotechnology
Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.
- Revenue
- +205.6%
- EPS
- +16.1%
- Free cash flow
- −65.9%
Quarter to September 2026, against a year earlier
86.43
3.42
+4.12%
Follow DNTH
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,857.58 | 2,868.55 | 3,017.14 | 781.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(100.31) | (111.51) | (139.69) | (33.87) | |
P/B ratio |
4.07 | 4.66 | 3.36 | 3.23 | |
Price to Tangible BV |
4.07 | 4.66 | 3.36 | 3.23 | |
EV/Sales |
1,549.34 | 2,402.79 | 2,185.36 | 583.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(24.04) | (29.44) | (22.41) | (9.20) | |
EV/FCF |
(23.95) | (29.38) | (22.38) | (9.18) | |
Quick Ratio |
29.40 | 25.79 | 29.06 | 13.16 | |
Current Ratio |
30.02 | 26.10 | 29.25 | 13.32 | |
Net Debt/EBITDA |
14.14 | 13.23 | 23.31 | 5.75 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.08 | 0.98 | 0.71 | 0.73 | |
Capex/Depreciation |
0.48 | 0.03 | 0.01 | 0.18 | |
Research and Development Expense of Revenue |
3,768.60% | 6,397.63% | 7,457.45% | 21,089.79% | |
Selling, General and Administrative Expense of Revenue |
1,163.80% | 1,781.47% | 2,692.87% | 3,496.48% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1,051.32% | 1,563.47% | 2,289.85% | 2,104.93% | |
Graham Net Nets |
0.16 | 0.16 | 0.27 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.54%) | (4.26%) | (4.92%) | (9.95%) | |
Free Cash Flow Yield |
(3.48%) | (2.85%) | (3.24%) | (8.12%) | |
Revenue per Share |
0.02 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.88) | (0.87) | (0.60) | (1.22) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.88) | (0.60) | (1.22) | |
Cash per Share |
14.61 | 15.83 | 23.14 | 10.47 | |
Shareholders Equity per Share |
21.65 | 20.92 | 25.01 | 12.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.65 | 20.92 | 25.01 | 12.78 | |
Free Cash Flow |
(50.70) | (49.16) | (28.87) | (47.12) | |
Working Capital |
827.52 | 863.15 | 1,081.63 | 378.71 | |
Capital Expenditures |
(0.37) | (0.18) | (0.01) | (0.14) | |
Net Current Asset Value |
821.22 | 856.29 | 1,074.34 | 371.92 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.30 | 0.24 | 0.02 | 0.49 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.79 | 0.07 | 1.12 | 0.43 | |
Average Payables |
6.10 | 5.90 | 6.77 | 7.15 | |
Average Assets |
926.85 | 769.67 | 797.73 | 452.47 | |
Average Common Equity |
893.94 | 737.55 | 764.96 | 422.94 |
Columns are period end dates · fundamentals updated 6 Nov 2026